APOE and Alzheimer disease: These findings are similar to data recently published by us in clinical cohorts, with E4 carriers exhibiting relatively higher SCAs and lower LCAs with AD even at the pre-clinical stages compared to controls and other APOE genotypes (Huguenard et al., 2022).